ArticleBMC microbiology2026
Molecular characteristics, clinical risk factors, and outcomes of Klebsiella pneumoniae bloodstream infections in infants.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundKlebsiella pneumoniae (KP) bloodstream infections (BSIs) are more common in immunocompromised patients and are associated with high rates of morbidity and mortality. Infants with an immature immune system and a lack of specific protective antibodies are susceptible to KP-BSIs. This study aimed to comprehensively investigate the clinical characteristics, antibiotic susceptibility profiles, treatment outcomes, and molecular characteristics of KP infections in these infants.
methodsBetween January 2017 and December 2024, a retrospective study was conducted at Guangxi Children’s Hospital, China. We used logistic regression to identify risk factors for carbapenem-resistant KP BSI (CRKP-BSI) and extended-spectrum β-lactamase KP BSI (ESBL-KP-BSI), as well as mortality-associated factors in KP-BSI patients. Whole-genome sequencing (WGS) was conducted on CRKP isolates. Subsequent genomic analyses included multilocus sequence typing (MLST), capsular serotyping, virulence gene, and antimicrobial resistance gene through Pathogenwatch, complemented by plasmid replicon identification via PlasmidFinder.
resultsDuring the study period, 98 patients with KP-BSIs were enrolled. Of these patients, 16 were infected with CRKP and 82 with carbapenem-susceptible KP (CSKP). Among 82 CSKP cases, 29 had ESBL-KP and 53 had non-ESBL-KP. Multivariate analysis identified carbapenem exposure as an independent predictor of CRKP-BSIs (OR: 4.37, 95% CI: 1.12–16.98, p = 0.03), and β-lactam/β-lactamase inhibitor administration independently predicted ESBL-KP BSIs (OR: 3.59, 95% CI: 1.12–11.56, p = 0.03). The independent risk factors for the 30-day mortality in KP-BSIs was mechanical ventilation (OR: 4.71, 95% CI: 0.97–22.94, p = 0.05). MLST analysis identified four sequence types, with ST7 being the most prevalent, followed by ST24, ST20, and ST37. Capsular serotyping revealed KL54 as the predominant serotype. Antimicrobial resistance gene profiling indicated that all isolates harbored multiple resistance determinants, with blaNDM−1 and blaCTX−M−14 being universally present. The most prevalent replicons were IncX3, IncFII(K), IncR, and IncFIB(K), which frequently co-occurred. Furthermore, bioinformatic analysis indicated that these CRKP strains carried multiple resistance genes, with the likelihood that they are localized on plasmids.
conclusionThis study underscores the need for stricter antibiotic stewardship, especially in limiting exposure to carbapenems and β-lactam/β-lactamase inhibitors, as well as minimizing invasive procedures (e.g., mechanical ventilation) to reduce multidrug-resistant KP-BSI incidence and improve survival outcomes in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.